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Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease of unknown cause,
characterized by the selective and progressive death of both upper and lower motoneurons,
leading to a progressive paralysis. Experimental animal models of the disease may provide
knowledge of the pathophysiological mechanisms and allow the design and testing of therapeutic
strategies, provided that they mimic as close as possible the symptoms and temporal progression
of the human disease. The principal hypotheses proposed to explain the mechanisms of
motoneuron degeneration have been studied mostly in models in vitro, such as primary cultures of
fetal motoneurons, organotypic cultures of spinal cord sections from postnatal rodents and the
motoneuron-like hybridoma cell line NSC-34. However, these models are flawed in the sense that
they do not allow a direct correlation between motoneuron death and its physical consequences
like paralysis. In vivo, the most widely used model is the transgenic mouse that bears a human
mutant superoxide dismutase 1, the only known cause of ALS. The major disadvantage of this
model is that it represents about 2%–3% of human ALS. In addition, there is a growing concern on
the accuracy of these transgenic models and the extrapolations of the findings made in these
animals to the clinics. Models of spontaneous motoneuron disease, like the wobbler and pmn mice,
have been used aiming to understand the basic cellular mechanisms of motoneuron diseases, but
these abnormalities are probably different from those occurring in ALS. Therefore, the design and
testing of in vivo models of sporadic ALS, which accounts for >90% of the disease, is necessary. The
main models of this type are based on the excitotoxic death of spinal motoneurons and might be
useful even when there is no definitive demonstration that excitotoxicity is a cause of human ALS.
Despite their difficulties, these models offer the best possibility to establish valid correlations
between cellular alterations and motor behavior, although improvements are still necessary in
order to produce a reliable and integrative model that accurately reproduces the cellular
mechanisms of motoneuron degeneration in ALS.
Introduction
Effective treatments for practically all diseases can only
result from the knowledge of their cellular and molecular
pathophysiological mechanisms. This is particularly evi-
dent in the case of diseases whose cause is still unknown
in spite of the remarkable progress of biomedicine in the
recent decades, such as devastating neurodegenerative dis-
eases, including Alzheimer's disease and amyotrophic lat-
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eral sclerosis (ALS). For the purpose of gaining insights
into such mechanisms, the design and use of experimen-
tal models is essential. In general, such studies are carried
out in vitro, in cell cultures, slices or organotypic cultures,
and in vivo. Whereas the former can give very useful infor-
mation regarding cellular and molecular mechanisms, the
experiments in whole living animal models obviously
reflect more closely the human disease, provided that the
symptoms and their development during time mimics as
close as possible those of the human disease. In this
framework, the purpose of the present article is to review
the available experimental animal models of ALS.
Amyotrophic lateral sclerosis, described in 1869 by the
French neurologist Jean-Martin Charcot, is a fatal adult-
onset neurodegenerative disease characterized by the
selective and progressive death of both upper and lower
motoneurons, leading to a progressive paralysis, respira-
tory depression and death usually within 2–5 years after
onset. Based on which type of motoneurons are primarily
affected, whether lower motoneurons, located in the ven-
tral horns of the spinal cord, or upper motoneurons,
located in the brainstem and the cerebral motor cortex,
ALS can be classified in two forms: spinal onset (~75% of
cases), characterized by muscle weakness and atrophy,
cramps, fasciculations, spasticity and paralysis, and bul-
bar-onset (~25% of cases), characterized by progressive
dysphagia and dysarthria, spasticity and hyperreflexia [1].
Because the neuronal loss in ALS is selective, the disease
generally does not cause major cognitive impairments
such as those occurring in other neurodegenerative dis-
eases like Alzheimer's and Huntington's. However, some
ALS patients may present changes in personality, irritabil-
ity, obsessions, poor insight and deficits in frontal execu-
tive tests [2]. In the majority of ALS patients, death is due
to respiratory failure caused by the denervation of the res-
piratory muscles and diaphragm. The prevalence of ALS is
about 2–6 cases/100,000 and the median age of onset is
55 years, although it can start at younger ages [3].
The disease occurs in sporadic and familial forms with
very similar clinical courses and common pathological
features, such as the presence of abnormal accumulations
of neurofilaments in degenerating motoneurons [4]. The
familial form of ALS (FALS) accounts for 5–10% of cases
and has an autosomal dominant pattern of inheritance,
whereas the sporadic form (SALS) accounts for the major-
ity of ALS cases (~90%). Among the FALS cases, about
20% are caused by missense mutations in the SOD1 gene
that codes for the enzyme Cu2+Zn2+ superoxide dismutase
1 (SOD1) [5]. However, the cause of most ALS cases is still
unknown and several hypotheses have been proposed to
account for the selective death of upper and lower
motoneurons. These include oxidative damage, axonal
strangulation and transport impairment, disorganization
of neurofilaments, protein misfolding and toxicity from
intracellular aggregates, mitochondrial dysfunction,
inflammation, apoptosis, and excitotoxic death arising
from the mishandling of glutamate [4,6-10]. Because the
clinical course of the disease is highly variable, the mech-
anism of motoneuron death may arise from the unfortu-
nate convergence of multiple factors rather than from a
single alternative.
The pathogenesis of ALS has been studied in autopsy sam-
ples, but this has not yielded reliable information in terms
of the pathophysiological mechanisms of motoneuron
degeneration during the progressive clinical stage, from
disease onset to the death of the patients. The pathological
hallmarks that have been found in the spinal cord of
autopsied ALS patients include the atrophy of dying
motoneurons with notable swelling of the perikarya and
proximal axons, intracytoplasmic neurofilament abnor-
malities, and the presence of Bunina bodies, spheroids
and strands of ubiquitinated material in degenerating
axons and in cell somas; this motoneuron pathology is
often accompanied by reactive gliosis [11].
Under these circumstances, experimental in vitro and in
vivo models have been developed to improve our under-
standing of the disease and have allowed the testing of
possible therapeutic strategies. However, these models
have many limitations and have not succeeded in design-
ing effective treatments to stop the course of the disease.
Therefore, an integrative model that reproduces the
chronic progressive motoneuron death and the main
characteristics of the disease is still needed.
Based on the multiple events considered to contribute to
the selective loss of motoneurons as targets for therapy,
many different drugs have been tested on their capacity to
alleviate or retard the symptoms of ALS patients and to
prolong their survival, but none has proved to be effective.
The only currently used compound that slightly slows dis-
ease progression and prolongs the survival of ALS
patients, with no improvement in muscle function, is rilu-
zole. This drug limits glutamate release from nerve end-
ings possibly by stabilizing the inactive state of voltage-
dependent sodium channels and by a G protein-coupled
intracellular pathway [12-16].
Mutations in superoxide dismutase 1 as cause of 
one form of familial ALS
Cu2+/Zn2+ superoxide dismutase 1 (SOD1) is an ubiqui-
tously expressed cytoplasmic enzyme that catalyzes the
dismutation of the superoxide radical (O2 
-) into hydro-
gen peroxide and molecular oxygen and is an important
free radical scavenging enzyme that protects cells against
oxidative stress. The copper atom is alternately reduced
and oxidized by superoxide, providing a reactive center
for its dismutation, while the zinc atom gives structural
stability to the protein; both cations are buried at the bot-Molecular Neurodegeneration 2009, 4:31 http://www.molecularneurodegeneration.com/content/4/1/31
Page 3 of 13
(page number not for citation purposes)
tom of an active site channel [17-19]. The disease-causing
SOD1 mutations are scattered throughout the primary
structure of the protein. More than 100 mutations have
been found [20-22], and all but one, SOD1D90A [23,24],
cause the dominantly inherited disease. Superoxide radi-
cal is a very reactive intermediate formed by the reduction
of O2 in the respiratory chain and is a powerful oxidant; it
is normally converted to hydrogen peroxide before it can
undergo other free-radical reactions. Hydrogen peroxide
is converted to water by catalase or glutathione peroxi-
dase, but it can also be decomposed to hydroxyl radical in
the presence of iron; this radical is highly reactive and can
damage lipids, proteins or nucleic acids.
It has been demonstrated that SOD1-mediated toxicity in
ALS is not due to the loss of its catalytic activity but instead
to a gain of function which confers one or more toxic
properties that are independent of the levels of dismutase
activity [25]. The main arguments against the importance
of loss of dismutase function are that SOD1 knockout
mice do not develop motoneuron disease [26] and that
levels of SOD1 activity do not correlate with disease in
mice or humans. In fact, some mutant enzymes retain full
dismutase activity [27,28], and chronic increase in the lev-
els of wild-type SOD1 (and dismutase activity) has no
effect on the disease [29] or even accelerates it [30]. The
acquired toxic property likely disrupts several basic cellu-
lar functions in neurons, including protein breakdown by
the ubiquitin-proteasome system, slow anterograde trans-
port, fast retrograde axonal transport, calcium homeosta-
sis, mitochondrial function, and maintenance of the
cytoskeletal architecture [7]. The toxicity can arise either
through aberrant chemistry, mediated by the misfolded
aggregated mutants, which can disregulate the redox equi-
librium [31] or produce loss or sequestration of essential
cellular components, for example by saturating the pro-
tein-folding chaperones and/or the protein-degradation
machinery [7,8,31]. This includes endoplasmic reticulum
stress and accumulation of the mutant SOD1 in micro-
somes [32,33]. The discovery of prominent cytoplasmic
inclusions in motoneurons and, in some cases, within the
astrocytes surrounding them in the SOD1 ALS mouse
model [29,30,34] and in autopsy samples from patients
with SALS and FALS [35-37] led to the hypothesis of toxic
protein aggregation. These inclusions are commonly
detergent-insoluble elements dispersed in the cytosol,
which have been characterized by ubiquitin and SOD1
staining [38,39]. The toxicity to motoneurons generated
by SOD1 mutants seems to be non-cell autonomous,
since mutant damage occurs not just within motoneurons
but also in non-neuronal cells, suggesting that neuronal
death depends, at least in part, on a contribution
from surrounding astrocytes and possibly other cell types
[40-42].
Other mutations as cause of familial ALS
A series of other mutant genes have been reported to cause
ALS in both familial and sporadic cases (see [43,44] for
comprehensive reviews), but the number of patients har-
boring these mutations is substantially low, and therefore
these mutations are not commonly used for modeling
ALS, although there are few exceptions such as alsin.
Alsin, the product of the ALS2 gene coded in chromosome
2q33 [45], is a protein with three putative guanine nucle-
otide exchange factor domains that has been found
altered in some FALS cases [46,47], with a higher preva-
lence in Tunisian and Pakistani populations [45,48]. Most
ALS2 mutations are deletions caused by abnormal stop
codons that produce a truncated dysfunctional protein
[49]. Homozygous expression of mutant alsin is responsi-
ble for early onset FALS, also known as juvenile ALS or
ALS2; this form progresses slower than the adult onset
forms [50]. Since juvenile ALS is inherited in a recessive
manner it is assumed that the proper function of alsin is
an elemental component of motoneuron physiology.
Unlike SOD1 mutations that cause a rather homogeneous
phenotype independently from the amino acid substitu-
tion, although subtle differences exist, ALS2  truncated
products cause a diversity of clinical outcomes depending
on the form generated by the specific mutation. Further-
more, mutations in alsin are not only responsible for pro-
voking ALS but for at least two other types of motoneuron
disease: primary lateral sclerosis and hereditary spastic
paraplegia (reviewed in [51]).
Recently, it was reported that mutations in the RNA/DNA
binding protein TDP-43 cause classical ALS with an auto-
somal recessive inheritance pattern (see [52] for review),
and shortly after this discovery another nucleic acid bind-
ing protein was found to be mutated in a British family
with FALS [53,54]. The discovery of these mutations may
allow the development of new experimental models for
ALS, although as we shall discuss later, such models might
be limited to reproduce the causes of motoneuron death
related to those specific mutations.
Glutamate-mediated excitotoxicity as a causal 
factor of ALS
Glutamate-mediated excitotoxicity generated by an exces-
sive glutamatergic synaptic transmission is considered a
probable mechanism leading to motoneuron degenera-
tion in both SALS and FALS. Excitotoxicity involves a mas-
sive influx of Ca2+ through glutamate receptors, triggering
the uncontrolled activation of deleterious processes that
eventually produce neuronal death [55,56]. Motoneurons
are highly vulnerable to intracellular calcium overload
due to their low calcium buffering capacity [57-60].Molecular Neurodegeneration 2009, 4:31 http://www.molecularneurodegeneration.com/content/4/1/31
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In spinal motoneurons, calcium entry is likely to occur
through calcium-permeable AMPA (α-amino-3-hydroxy-
5-methylisoxazole-4-propionate)-type receptors. Func-
tional AMPA receptors are composed of four subunits,
GluR1-GluR4, in various combinations [61]. Subunit
GluR2 determines the calcium permeability because the
presence of at least one GluR2 in the receptor structure
makes it impermeable to the cation [62,63]. In addition,
the posttranscriptional modifications that edit the Q/R
site of the GluR2 impede the calcium flux through the
pore [64]. Therefore, activation of AMPA receptors lacking
the GluR2 subunit or without its posttranscriptional edi-
tion may have significant pathophysiologic consequences
that could be involved in ALS. In fact, spinal motoneurons
are particularly vulnerable to agonists of the AMPA-type
receptors probably because of a large calcium influx, both
in vitro [56,65,67-72] and in vivo [73,74].
Glutamatergic synaptic transmission is rapidly terminated
by the neurotransmitter uptake from the synaptic cleft
into neurons and glia, a process carried out by high affin-
ity glutamate transporters. Five of these transporters have
been identified and cloned, and their location in the cen-
tral nervous system has been determined. Excitatory
amino acid transporter 2 (EAAT2), also called glutamate
transporter 1 (GLT1) in rodents, is the most abundant and
is present almost exclusively in astrocytes [75]. In ALS
patients, post-mortem analysis of the motor cortex and
the spinal cord revealed a reduction in the content of
EAAT2 [69,76,77]. These findings led to the hypotheses
that malfunction of EAAT2 might be an important cause
of motoneuron death in ALS, but it is still unknown if the
loss of glutamate transporters in the tissue of ALS patients
is a cause or a consequence of neuronal loss [78]. In addi-
tion, even when increased levels of glutamate in the cere-
brospinal fluid and plasma of SALS patients have been
described [79,80], this increase occurs in only ~40% of
patients [81,82], suggesting that elevated glutamate does
not seem to be the triggering factor for motoneuron death
in SALS. Furthermore, recent findings from our laboratory
do not support this hypothesis, because the acute [73] and
chronic [83] pharmacological blockade of glutamate
transport in the rat spinal cord in vivo, which results in
increased concentrations of extracellular glutamate, failed
to cause motoneuron death or motor deficits. Also, no
neuronal damage was observed in the hippocampus and
motor cortex of transgenic FALS mice in which extracellu-
lar glutamate was elevated by transport blockade [84].
Oxidative stress in ALS
There are many data supporting the involvement of oxida-
tive stress in ALS pathogenesis. Analysis of post mortem
tissue from ALS patients has revealed an increased oxida-
tive damage of cell components as compared to controls,
like oxidized DNA [85,86] and formation of carbonyl
[85,87] and nitrotyrosine [88-90] derivatives in proteins.
Furthermore, lipid peroxidation and protein glycoxida-
tion were found increased in spinal cord motoneurons
and glial cells [91]. Markers of oxidative damage have also
been analyzed in cerebrospinal fluid and plasma from liv-
ing ALS patients during the course of the disease, showing
enhanced DNA oxidative damage [92,93], lipid peroxida-
tion [94-97] and elevation of nitrotyrosine [98], although
the latter result is controversial [99]. Increased oxidative
damage in macromolecules has also been demonstrated
in the transgenic mutant SOD1 mouse, [100-104] suggest-
ing that oxidative stress could be involved in FALS patho-
genesis. In models in vitro, spinal motoneurons exposed
to an excitotoxic insult by stimulation of AMPA receptors
produced a mitochondrial calcium overload that triggered
mitochondrial depolarization and generation of ROS
[105].
All these data support the hypothesis of oxidative stress as
a mechanism that contributes to motoneuron injury in
ALS, but it is still unclear whether oxidative stress is a
cause or a consequence of the disease, since it may result
from other cellular processes like excitotoxicity, mito-
chondrial dysfunction or protein aggregation.
Protein aggregation in ALS
The aggregation of misfolded proteins leads to cellular
degenerative processes that ultimately cause neuronal
death. This kind of disturbances is well characterized for
neurodegenerative diseases like Alzheimer's, Parkinson's
and Huntington's diseases, whereas in ALS, besides the
previously discussed aggregation of mutant SOD1 in
FALS, some toxic intracellular inclusions have been
described in both SALS and FALS. The best described are
changes in neurofilament composition that generate alter-
ations in perykaria and proximal axons of motoneurons,
a pathogenic characteristic of ALS described several years
ago [106]. In some cases mutations were found in the
heavy subunit of neurofilaments [107-109], and trans-
genic mice harboring mutant or overexpressed neurofila-
ment subunits H and L show a motoneuron pathology
reminiscent of that occurring in ALS [110,111].
Experimental models for the study of ALS
The rationale of the foregoing review on the advances in
the knowledge of the mechanisms of motoneuron death
and the hypotheses on the pathophysiology of ALS is to
provide a framework for analyzing the experimental
approaches that have been developed when attempting to
create valid experimental models of the disease. These
include experiments in vitro using diverse spinal cord
preparations, and whole animal experiments, which
include animals with spontaneous motoneuron degener-
ation, transgenic rodents, and animals in which spinal
motoneuron death was produced with pharmacological
tools.Molecular Neurodegeneration 2009, 4:31 http://www.molecularneurodegeneration.com/content/4/1/31
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In vitro models
Spinal cord cultures
Primary spinal cord cultures have been established and
used to study the morphological, biochemical and elec-
trophysiological characteristics of motoneurons for many
years [112]. Generally, the tissue for cellular culture is
taken from 12–14 days-old rodent embryos or 6–7 days-
old chicken embryos, the spinal cord is dissociated by
mechanical and enzymatic procedures and then plated on
matrix-coated dishes. Motoneurons are relatively easy to
identify in culture due to their large size (25 to 30 μm of
diameter), but because they are present in very small
quantities in the spinal cord (in a transversal section at the
lumbar segment of the rat spinal cord there are less than
25 motoneurons in each side), motoneuron enriched cul-
tures are often used instead of mixed primary cultures.
Motoneuron enrichment is achieved by several methods.
For example, the cellular suspension obtained after spinal
cord homogenization is centrifuged in a metrizamide
cushion, that separates cell bodies by cellular densities;
motoneurons have a relatively low cellular density and
the enriched fraction is identified by biochemical analyses
of acetylcholine production [113].
Further purification of the motoneuron population can be
achieved by the immuno-recognition of the nerve growth
factor receptor p75 that motoneurons express since early
embryonic stages. A specific antibody for the p75 receptor
is immobilized in a Petri dish on which a suspension of
cells is poured, and motoneurons specifically adhere to
the antibody coated surface increasing their concentration
[114]. Because motoneurons require a large variety of
trophic factors to survive, the enriched cultures are gener-
ally seeded on top of a spinal glial feeder layer, usually
obtained from the same spinal tissues that motoneurons
came from. Enriched motoneuron cultures can also be
obtained by flow cytometry. Motoneurons are labeled
with fluorescent tracers that are injected in the developing
muscle and retrogradely transported by the axons to the
neuronal somas in the spinal cord, and then the labeled
cells can be sorted [115]. Another way to obtain these cul-
tures is to express an enhanced green fluorescent protein
under a specific motoneuron promoter in embryonic
stem cells; marked cells can be sorted and then differenti-
ated into motoneurons in culture [116].
Modeling a complex disease in such a reduced and limited
system has a series of inconveniences, but still, important
information on some intracellular mechanisms can be
obtained by studying the physiology of motoneurons. For
example, using these systems it was first demonstrated
that motoneurons are particularly vulnerable to glutama-
tergic excitotoxicity trough AMPA receptors [66], that the
toxicity underlying this process is mediated by Ca2+
[71,105] and that glutamate preferentially stimulates the
production of reactive oxygen species in motoneurons in
comparison with other neuronal types of the spinal cord
[117].
A major shortcoming of these systems is that the condi-
tions in which motoneurons exist must be substantially
modified. For instance, the mentioned particular vulnera-
bility of motoneurons to AMPA in culture is only seen
when extracellular calcium concentration is raised from
physiological 2 mM to 10 mM [66,71,105]. Also, the fact
that the ratio motoneurons:glia is altered is not trivial,
since non-neuronal cell types play a fundamental role in
the pathogenesis of this disease and accumulating experi-
mental evidence indicates that ALS is a non cell-autono-
mous disease, meaning that its origin may be localized
not only in motoneurons, but in the surrounding spinal
cells as well [40,41,118-120]. Thus, although cultures of
glial cells have helped to elucidate the participation of
other cellular types in the development of ALS, like micro
and astroglia toxicity due to the expression of mutant
SOD1, the information obtained from these studies is
limited to the particular experimental conditions
employed.
NSC-34 cells
Establishing a cell line of immortalized neurons in culture
is a difficult task, mainly because of the intrinsic proper-
ties of the neuronal lineage, including their null capacity
to proliferate when they are fully differentiated. In an
attempt to circumvent this problem, a hybrid cell line
(NSC-34) of neuroblastoma (a highly proliferative neuro-
nal cell type) and spinal cord motoneurons from enriched
primary cultures, was produced by fusing the two cell
types [121]. In this hybrid line some of the motoneuron
characteristics are present, like acetylcholine synthesis,
storage and release, action potential generation, expres-
sion of neurofilament proteins and association with neu-
romuscular synapse-specific basal lamina glycoproteins.
The NSC-34 line expressing mutant SOD1 is considered a
cellular model of ALS. In these cells some features of
motoneuron alterations have been described, for exam-
ple, Golgi apparatus fragmentation [122], and mitochon-
drial dysregulation [123]. They have also been used to
study in vitro some of the mechanisms of mutant SOD1
toxicity [124-126]. Nonetheless, NSC-34 cells also retain
characteristics of the neuroblastoma linage, like an
enhanced N-myc action [121]. N-myc is an oncogene that
directs diverse cellular responses, especially those
involved in proliferation [127]. For the study of the mech-
anisms of neuronal death and its prevention by possible
therapeutic agents the effects of N-myc could obstruct the
underling mechanisms, making this model faulty.
Organotypic cultures
All neurons exist in a specific tissue context where the sur-
rounding cellular types shape the biochemical, electro-Molecular Neurodegeneration 2009, 4:31 http://www.molecularneurodegeneration.com/content/4/1/31
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physiological and morphological characteristics of each
neuron. Motoneuron excitatory or inhibitory inputs and
outputs from their afferences and interneurons, as well as
trophic support from surrounding glia and its reactivity in
response to neuronal death, modulate important charac-
teristics of the cellular and molecular processes that occur
in ALS. When spinal cord is disgregated and plated on
dishes, all these important cellular interactions are lost.
One way to preserve the tissue structure for in vitro ana-
lyzes is to cultivate an entire slice of the spinal cord in an
organotypic culture. With this method, spinal cord slices
obtained from neonate pups are chopped into 400 μm
thick sections that can be cultured for as long as 3 months.
Motoneurons in this type of preparations retain their met-
abolic characteristics like choline acetyltransferase and
acetylcholinesterase activities [128].
Slow motoneuron degeneration in organotypic cultures
has been induced by the chronic exposure to the gluta-
mate transporter blocker threo-β-hydroxyaspartate (THA)
[129]. Using this system it has been reported that neuro-
trophic factors are able to protect motoneurons from exci-
totoxic death [130,131]. As with the cell cultures, a major
shortcoming of organotypic systems is that they do not
always accurately reproduce what would be happening in
an in vivo system and even less in an ALS patient. For
example, while the glutamate transport blockade is highly
toxic for motoneurons in organotypic cultures [129-131],
as already mentioned the blockade of glutamate uptake in
vivo is innocuous for motoneurons [73,83,84].
In vivo models
Spontaneous genetic defects that cause motoneuron degeneration
The oldest known model of spontaneous motoneuron
alterations is the wobbler mouse. This mouse harbors a
mutation in the wr locus that has been mapped in chro-
mosome 11 [132]. It was recently found that this gene that
codes for the vacuolar-vesicular protein sorting 54
(Vps54) has the missense mutation L967Q in the wobbler
mouse [133]. Homozygous expression of the mutant wr
gene causes the death of motoneurons in the cervical por-
tion of the spinal cord, affecting mainly the somas, and in
consequence, causing a proximal axonopathy [134]. The
pathology presented by these animals may have a glial ori-
gin, since they develop astrocytic defects and an increased
astrocyte reactivity that seems independent from motone-
uron death [135].
The mechanisms of neurodegeneration in the wobbler
mice are so far unidentified. Excitotoxic processes seem
not be involved, since glutamate transporters are
expressed normally, extracellular glutamate levels are
unchanged [136], and AMPA receptor antagonists have
no effect on motor behavior and neuronal loss [137].
Also, results of TUNEL staining of fragmented DNA [138],
and activation of caspases suggest that apoptosis is not
involved in neuronal death in these mice [139].
Another model of spontaneous motoneuron death is a
mouse that suffers a progressive motoneuronopathy
(pmn), caused by the homozygous expression of the
mutant tubulin-specific chaperone E [140,141]. These
animals develop a progressive caudo-cranial degeneration
of the motor axons and die at few weeks after birth [142].
The main pathological characteristic of the pmn mouse is
a distal axonopathy with minor alterations of neuronal
somas, an alteration different from the ALS pathology
[143]. Although the pathophysiology of motoneuron
death in these animals is not the same as in ALS, the neu-
roprotective potential of some agents, like certain trophic
factors [144,145] or anti-excitotoxic compounds [146]
have been shown to be partially effective.
The wasted mutant mouse with genotype wst/wst  is
another murine model of spontaneous spinal neurode-
generation. These animals develop a hindlimb paralysis,
not necessarily due to motoneuron loss but to cell vacu-
olization [147]. There are reported cases of spontaneous
motoneuron disease in larger animals. A spontaneous dis-
ease of the horse, known as equine motoneuron disease,
is characterized by a generalized weakness, progressive
muscle atrophy and loss of motoneurons in the spinal
cord and brainstem [148]. In dogs, a condition named
hereditary canine muscular atrophy is caused by a mild
loss of motoneurons in spinal cord and brainstem and
neurofibrillary swellings in proximal axons [149]. These
animals may mimic in some way the pathology underly-
ing sporadic ALS, but their use in experimental studies is
clearly complicated.
Genetically modified models
- Alsin knock out mice
Human mutations in the alsin protein encoded by the
ALS2 gene in some FALS cases were mentioned in a previ-
ous section. ALS2 knock out mice have been developed
and shown to be deficient in motor coordination and
motor learning [150], to have abnormalities in endosome
trafficking [151,152], as well as axonal degeneration [153-
155] and increased susceptibility to oxidative stress [150].
Although no overt motoneuron degeneration is present,
these animals appear to be a good in vivo model for the
study of the alterations of motoneuron physiology that
take place before cellular death such as axonal impair-
ment, but, as in the case of mutant SOD1 transgenic mice
described next, the processes studied may mimic only
those occurring in patients with this type of genetic alter-
ations.
- Transgenic mutant SOD1 rodents
A major breakthrough in the ALS research was the discov-
ery that ~20% FALS cases were due to mutant SOD1 [5].Molecular Neurodegeneration 2009, 4:31 http://www.molecularneurodegeneration.com/content/4/1/31
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Almost immediately after this finding, transgenic mice
that express mutant human SOD1 were developed. The
initial mutations produced the substitution of glycine for
alanine at position 93 (G93A), and of alanine for valine at
position 4 (A4V) [156]. Other SOD1 mutations have been
expressed in transgenic mice. The commonest, in addition
to G93A and A4V, are glutamate for arginine substitution
at positions 37 (G37R) [157] and 85 (G85R) [158]. The
phenotype expressed by these mice, regarding the age at
symptoms onset and their severity is directly proportional
to the amount of mutant protein expressed in the tissue
[159], lending further support to the hypothesis of the
acquired toxic function of mutant SOD1 mentioned
before.
The disease in transgenic mice begins with hindlimb
weakness, impaired leg extension and shortened stride
length, and continues to complete paralysis of the limbs,
principally the rear ones, within few days [156]. Cellular
alterations are mainly characterized by vacuolar degener-
ation of motoneurons and their processes at the early
stages, followed by neuronal loss and atrophy of the ven-
tral horns in the spinal cord at the late stages; the most
damaged tissue is the spinal cord, but the medulla, pons
and midbrain are affected as well [34]. In addition, mice
expressing the G85R mutation in the murine SOD1
develop paralysis due to motoneuron loss similar to that
presented by the transgenic expression of human mutant
SOD1 [160]. Transgenic rats expressing mutant human
SOD1 have also been developed and display a similar
pathology [161,162].
Since no symptomatic or pathological evident differences
exist between FALS and SALS, it has been assumed that the
mechanisms underlying both types of the disease are
shared. Therefore, transgenic SOD1 animals have been
extensively used in numerous studies related to ALS, prin-
cipally because the phenotype they display is elicited by
the only proven cause of the disease. In this FALS model
all the primary hypothesis on ALS origin have been put to
challenge, including oxidative stress [31,163,164], excito-
toxicity [84,165], apoptosis [39,166,167], protein aggre-
gation [39], axonal dysfunction [168], mitochondrial
failure [40,166,167], endoplasmic reticulum stress
[32,33,169], and practically every other suspected mecha-
nism. This model has also been the golden standard for
drugs and therapies testing at experimental stages. None-
theless, the major weakness of this FALS model is that it
reproduces the mechanism of neuronal death that occurs
in only ~2% of ALS cases. Therefore, it is not completely
accurate to extrapolate the findings made in this model to
the processes occurring in patients that do not bear muta-
tions in SOD1 [165]. In addition, a meta-analysis of a vast
number of data on the therapeutic action of many drugs
in SOD1 mutant mice revealed that most of these experi-
ments show serious methodological problems, such as a
bias for reporting beneficial effects, small number of ani-
mals, lack of randomization and blinding and the initia-
tion of the treatment prior to symptoms onset, something
that cannot be done in human ALS [170]. These problems
may be the reason for the lack of reproducibility of the
therapeutic effect of several drugs when tested in large
cohorts and in blind manner, as was described in detail in
another recent study [171]. This clearly urges the necessity
to test these potential treatments in non familial related
models of motoneuron degeneration.
Models of non-genetic spinal motoneuron degeneration
There are much less animal models for SALS than for
FALS, in spite of the fact that it accounts for >90% of the
cases. Taking advantage of the knowledge on motoneuron
death by excitotoxicity discussed above, our group has
developed some acute and chronic experimental models
that should be useful for studying the mechanisms of spi-
nal motoneuron death and for testing potential therapeu-
tic agents. The objective of the first experiments in this
effort was to test whether the excitotoxicity produced by
N-methyl-D-aspartate and AMPA/kainate receptor ago-
nists or by endogenous glutamate might induce spinal
motoneuron death and paralysis in the living rat. The
experimental procedure used was microdialysis in the
lumbar spinal cord, which permits the perfusion of drugs
and at the same time the collection of extracellular fluid
for the measurement of glutamate and other amino acids.
Using this method we found that increasing the concen-
tration of endogenous extracellular glutamate through the
inhibition of glutamate transport failed to cause motor
alterations or motoneurons loss, results that do not sup-
port the hypothesis of glutamate-mediated excitotoxicity
resulting from the loss of glutamate transporters. On the
other hand, perfusion of AMPA produced permanent
paralysis of the ipsilateral hindlimb and a remarkable loss
of spinal motoneurons, which started ~3–6 h after the
beginning of the perfusion and progressed until reaching
a maximum at 12 h, when practically all motoneurons in
the spinal segment studied were lost. All these effects were
prevented by the AMPA receptor antagonist 2,3-dihy-
droxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX)
and by an inhibitor of proteases [73,172].
The fact that the motoneuron death in our model begins
only 3–6 h after the infusion of AMPA, and becomes com-
plete at 12–24 h led to the hypothesis that the entry of cal-
cium, probably through the calcium-permeable AMPA
receptor channel, induces a delayed deleterious process
leading to motoneuron death. To test this hypothesis,
AMPA was co-applied with 1-naphthyl acetyl spermine
(NAS) a selective blocker of the AMPA receptor that lacks
the GluR2 subunit [67,173-175]. This compound signifi-
cantly prevented the selective spinal motoneuron loss andMolecular Neurodegeneration 2009, 4:31 http://www.molecularneurodegeneration.com/content/4/1/31
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the subsequent paralysis [74], indicating that rat spinal
cord motoneurons possess functional calcium-permeable
AMPA receptors lacking GluR2 and suggesting that the cel-
lular process leading to motoneuron death in this model,
in vivo, is triggered by an increase of intracellular calcium
via these receptors. The hypothesis that such an increase is
responsible for the damage was confirmed by the co-per-
fusion of the intracellular calcium chelator 1,2-bis-(o-
aminophenoxy)-ethane-N,N,-N',N'-tetraacetic acid
tetraacetoxy-methyl ester (BAPTA-AM) with AMPA, which
was as effective as NAS in the prevention of the motoneu-
ron damage and the paralysis [74]. The relevance of these
findings is noteworthy because, differently from the
experiments in vitro mentioned in a previous section, the
neuronal death due to increased cytoplasmic Ca2+ occurs
under the physiological extracellular concentration of the
cation (2 mM). Altogether, these data suggest that AMPA
receptors may have an important role in the development
of ALS.
The main limitation of the model discussed above is that
the paralysis develops within a few hours, whereas
motoneuron death in ALS is a chronic process that takes
lengthened time periods. For this reason, we designed a
different experimental approach, allowing the continuous
slow infusion of AMPA in the spinal cord during several
days using osmotic minipumps. This procedure generated
a chronic model of spinal motoneuron degeneration
induced by excitotoxicity, because it produced progressive
motor impairment and motoneuron death along several
days, depending on the AMPA concentration, resembling
the characteristics of neurodegeneration and paralysis that
are present in both ALS patients and FALS rodents [176].
Interestingly, we demonstrated that the coinfusion of vas-
cular endothelial growth factor (VEGF) with AMPA
remarkably protected against the deleterious chronic
effect of the latter, indicating that this chronic model may
indeed be useful for testing therapeutic strategies for ALS
[176].
We have thus developed in vivo models of acute and
chronic spinal motoneuron degeneration, in the absence
of altered genetic components, which are useful for stud-
ying the mechanisms of this degeneration and for assay-
ing potential neuroprotective compounds. As discussed
throughout this article, this is relevant in view of the need
of experimental animal models that reproduce motoneu-
ron degeneration in processes such as sporadic ALS, which
are not related to genetic alterations and occur in the great
majority of ALS cases. The main limitation of our model
is that, although glutamate-mediated overactivation of
AMPA receptors may be a relevant mechanism of spinal
motoneuron degeneration in ALS, convincing evidence
that this occurs in the human disease has not yet been
obtained.
Conclusion
In spite of the high complexity of ALS, it is clear that great
progress has been made regarding the mechanisms of
motoneuron death. However, one of the strongest obsta-
cles is the insufficient information on the cause of the
selectivity of motoneuron degeneration, because many of
the postulated mechanisms are common for the death of
other types of neurons located in several brain regions.
This is the case, for example, of Parkinson's and Alzhe-
imer's diseases. The intracellular Ca2+-dependent neuro-
nal death via overactivation of Ca2+-permeable AMPA
receptors may be an important factor for this selectivity,
because of the abundance of this type of glutamate recep-
tors in spinal cord motoneurons.
It is also evident that valuable data have been obtained
from experimental approaches in vitro, and that the com-
bination of these results with those generated in models
in vivo may lead to a better understanding of the patho-
physiology of the disease and therefore to the design of
effective therapeutic measures. Nevertheless, it appears
that the limitations of the models in vitro are far greater
than those of in vivo models, despite the difficulties of the
experiments in vivo and their interpretation, correlations
between cellular alterations and motor behavior can only
be obtained in the whole animal.
Most of the experimental models of ALS are in fact FALS
models, because they are transgenic rodents expressing
human mutant SOD1. It is therefore very relevant to
develop in vivo models of SALS, responsible for >90% of
all ALS cases. Such models can be generated by applying
the limited knowledge on the mechanisms already availa-
ble, such as those related to excitotoxicity.
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